Diabetic characteristics and alveolar bone loss in streptozotocin- and streptozotocin-nicotinamide-treated rats with periodontitis

Background and Objective Experimental models showing variable diabetic status are necessary to understand the relationship between diabetes and periodontitis. The streptozotocin (STZ)‐induced diabetes model allows control of diabetic status by nicotinamide (NA), which protects against STZ‐induced β‐...

Full description

Saved in:
Bibliographic Details
Published in:Journal of periodontal research 2014-12, Vol.49 (6), p.792-800
Main Authors: Kim, J-H., Lee, D-E., Choi, S-H., Cha, J-H., Bak, E-J., Yoo, Y-J.
Format: Article
Language:English
Subjects:
Alveolar Bone Loss - etiology
Animals
Blood Glucose - analysis
Body Weight
bone loss
Bone Matrix - pathology
Bone Resorption - etiology
Dentistry
Diabetes Mellitus, Experimental - blood
Diabetes Mellitus, Experimental - complications
Furcation Defects - etiology
Gingiva - pathology
Glucose Tolerance Test
Hyperglycemia - blood
Hyperglycemia - complications
Insulin - blood
Insulin-Secreting Cells - drug effects
Leukocytes, Mononuclear - pathology
Male
Molar - pathology
Neutrophils - pathology
Niacinamide - administration & dosage
nicotinamide
periodontitis
Periodontitis - complications
RANK Ligand - analysis
Rats
Rats, Inbred F344
Streptozocin
streptozotocin
Tibia - pathology
Vitamin B Complex - administration & dosage
Weight Loss
X-Ray Microtomography - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and Objective Experimental models showing variable diabetic status are necessary to understand the relationship between diabetes and periodontitis. The streptozotocin (STZ)‐induced diabetes model allows control of diabetic status by nicotinamide (NA), which protects against STZ‐induced β‐cell necrosis. Therefore, we compared diabetic characteristics and alveolar bone loss in STZ‐ and STZ‐NA‐treated rats with periodontitis. Material and Methods STZ‐treated rats were generated by intravenous (IV) administration of STZ (50 mg/kg). STZ‐NA‐treated rats were induced by intraperitoneal administration of NA (270 mg/kg) 15 min before IV administration of STZ (65 mg/kg). Periodontitis was induced by ligature around the left mandibular first molar 1 wk after injection. Blood glucose level, glucose tolerance and serum insulin levels were determined at day 0 and/or 20 after ligature. At day 20, tibia bone loss was assessed using micro‐computed tomography and hematoxylin and eosin staining. Alveolar bone loss was histologically measured as the distance of the cementoenamel junction to the alveolar bone crest in distal and the percentage of periodontal ligament area in the first molar furcation, respectively. The number of inflammatory cells, receptor activator of nuclear factor kappa‐B ligand (RANKL)‐positive cells and the area of osteoid were determined. Results In STZ‐treated rats, obvious hyperglycemia over 300 mg/dL and severe body weight loss were observed. The insulin level was approximately 14% compared to that of control rats. STZ‐NA‐treated rats were impaired in glucose tolerance compared to control rats; however, body weight and insulin levels were not significantly different. Tibia bone loss was increased in STZ‐treated rats, but significant change was not observed in STZ‐NA‐treated rats compared to control rats. In ligatured teeth, alveolar bone loss was increased in both STZ‐ and STZ‐NA‐treated rats compared to control rats. Alveolar bone loss, the number of inflammatory cells and RANKL‐positive cells in STZ‐treated rats were greater than in STZ‐NA‐treated rats. The area of osteoid decreased in STZ‐treated rats compared to control, but not STZ‐NA‐treated rats. Conclusion These results indicate that STZ‐ and STZ‐NA‐treated rats exhibit diabetic characteristics similar to type 1 diabetes mellitus and a pre‐diabetic state, respectively. In addition, alveolar bone loss in response to periodontitis and tibia loss depend on diabetic status. Diabetic st
ISSN:0022-3484
1600-0765
DOI:10.1111/jre.12165